

## **BACKGROUND AND PURPOSE**

The *Advanced Practitioner Society for Hematology and Oncology* (APSHO) is pleased to offer the Patient Advocacy Poster track during JADPRO Live, an annual conference for advanced practitioners (APs) in oncology and hematology. Since the inaugural offering of this poster track in 2022, patient advocacy posters have provided valuable insight into patient issues and available resources as well as connection opportunities between patient advocacy organizations and APs.

The mission of APSHO is to improve the quality of care for patients on the cancer journey by supporting critical issues in educational, clinical, and professional development for APs. APSHO comprises more than 6,400 APs in oncology and hematology, including nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists. We believe an interdisciplinary team approach to cancer treatment offers the best support for the outcomes, quality of life, and survivorship of our patients. APs understand that the importance of the patient perspective cannot be overstated, and they are uniquely positioned to incorporate feedback and insight from patients and their advocates into clinical practice. Through the Patient Advocacy Poster track, we can identify best practices for key components of care including communication, education, symptom management, and caregiver support. Gaining a better understanding of the patient's perspective provides ideas and insights for improving the overall quality of cancer care.

## **INVITATION TO SUBMIT**

APSHO and the JADPRO Live conference chair invite patient advocacy organizations and patients to partner in submitting abstracts for consideration of poster presentation during JADPRO Live 2026, to be held October 15-18 at the Minneapolis Convention Center in Minneapolis, Minnesota.

### **SUBMISSION DEADLINE – July 1, 2026, by 11:59 PM PDT**

Abstract submitters must complete all requirements by **11:59 PM PDT on Wednesday, July 1, 2026**, for the abstract to be considered for presentation in the Patient Advocacy Poster track by APSHO.

## **ABSTRACT SUBMISSION GUIDELINES**

### Who may submit

- Patient advocacy groups involved in cancer care
- Patients on the cancer care continuum, partnering with a patient advocacy group
- Caregivers of patients with cancer, partnering with a patient advocacy group

*Note: A caregiver is defined as a spouse, family member/loved one, friend, neighbor, or other non-healthcare provider assisting the patient during the cancer journey.*

### Examples of topics for submission

- An intervention, guideline, practice, or procedure with outcomes demonstrating a positive impact on care or quality of life
- An example of a collaboration between patient and health care team measuring improved care results
- Care interventions that resulted in outcomes showing improved symptom or side effect management
- Processes that resulted in evidence of improved communication, access to care, clinic experience, engagement, self-care, or support
- Evidence of impact of advocacy initiatives, education, support methods, assistance programs, complementary therapies, patient/caregiver support, survivorship care, research

### **Important Information Regarding Content for Abstract Submission**

Abstracts may not mention specific medications, therapies, devices for treatment or biopharmaceutical companies.

Abstract content should focus on specific initiatives, processes, education, or other efforts that have resulted in outcomes impacting patient care and support; **please include a description as well as results in the body of your abstract.**

JADPRO Live will accept submissions for review that are new, original content or an encore presentation from an approved oncology conference. \*

**Abstract/poster content previously displayed during any JADPRO Live conference may not be resubmitted.**

\* If previously presented, the author is responsible for obtaining applicable permissions and notifying the abstract coordinator.

### Submission process

All abstract details will be submitted via an electronic submission system.

**Submissions must be completed by the deadline of July 1, 2026, for an abstract to be reviewed.**

### **REQUIREMENTS FOR SUBMISSION**

The submission system is set up as tasks to gather all required information for submissions and contains instructions for completing each task. Submitters are encouraged to begin their submissions early and may save their work and come back to complete it, up until the submission deadline.

### **Submitter Tasks**

- Patient advocacy organization submitters: full name, credentials as applicable, title/position, organization name, email, phone number, and address
- Patient submitters: full name, email, phone number and address; must have at least one advocacy organization representative co-author
- Abstract title (75 characters or less)
- Complete body of abstract organized by subheadings (500 words or less)
- Co-author profile information, if applicable

- Declaration of the role of the authors in the work/content presented in the abstract
- Acknowledgement of AI guidelines and disclosure of AI utilization
- Confirmation of original authorship (completed by submitting author)
- Author disclosure forms (each author completes online)
- Consent for abstract review and sharing of identifiable information (if patient submitting)
- Permissions, if applicable (may be uploaded as supporting documentation)
  - Patient advocacy groups submitting abstracts containing identifiable patient information must upload a statement of permission from the patient.
- References, if applicable (encouraged but not required; may be uploaded as supporting documentation)
- Statement of need for assistance, if applicable. Statements of need are optional but must be uploaded at the time of submission. Financial assistance for poster presentations may be available.

Note: It is preferred that the lead author submits the abstract and presents the poster if the abstract is accepted. If a co-author on the abstract will be attending the conference and presenting the poster, that co-author should be the author who submits the abstract. If extenuating circumstances occur before the conference, and it is necessary for an author different than the submitter to present, the author must have been a co-author on the original submission, and the abstract submission coordinator should be notified as soon as possible. **Authors may not be added or substituted and changes to the submission are not permitted after the submission deadline.**

#### Abstract title

The title at the time of submission will be the final title used in all references to the abstract and poster.

**Acronyms and abbreviations are not permitted in the title.** The title is not included in the word count.

#### Abstract body and word count

Abstracts must be organized by section headings and should be no more than 500 words. Section headings are included in the word count. Acronyms may be used within the abstract if the word is spelled out at first use, with the acronym following in parentheses. Citations are not required or preferred in the body of the abstract. (See section on references and permissions below).

#### Section headings

The abstract should provide a meaningful snapshot of what will be presented in more detail within a poster, and must be organized with short, one-word section (paragraph) headings. Section headings are included in the word count. Examples of common section headings:

- Background (other options: Context, Setting)
- Intervention (other options: Process, Actions)
- Findings (other options: Discovery, Conclusions)
- Implications (other options: Discussion, Recommendations)

#### Tables and Figures

Tables and figures are not allowed in the body of the abstract but may be used in poster development.

#### References and Permissions

References and/or permissions may not be included in the body of the abstract and therefore are not included in the word count. Permissions are required if identifying patient information is shared. References for the

abstract are optional but welcomed and should be in list format. Permissions and references must be uploaded as a PDF.

### Statement of need

Limited financial support may be available for poster presentation of accepted abstracts. Statements of need are optional but must be uploaded during submission, describing the type of support requested.

### **REGARDING ARTIFICIAL INTELLIGENCE (AI)**

AI-based tools and technologies include but are not limited to large language models, generative AI, and chatbots. JADPRO Live, following the standards of the *Journal of the Advanced Practitioner in Oncology* (JADPRO), has adapted guidelines regarding AI in abstract submission and poster presentation.

- Human authors must be heavily involved in the writing process and are ultimately accountable for the content of the work.
- AI and AI-assisted technologies should not be listed as an author or co-author or be cited as an author.
- AI tools used to assist with grammar, spelling, formatting, and reference clean up do not need to be disclosed.
- JADPRO Live does not accept abstracts focused on author opinion or perspective that have used AI to generate text.
- Where authors use AI in research such as data acquisition or analysis, it must be disclosed in the Methods section, with the version number, data accessed, and manufacturer name described, along with the disclosure.
- Where authors use AI to create graphics for posters, the role of AI in creating the graphic must be specified in the legend.
- Reviewers of abstracts may not use AI tools when reviewing work for peer review.

Abstract submitters are asked to attest to authorship within the submission process. If AI has been utilized for abstract development beyond grammar, spelling formatting, and/or reference clean-up, the submitting author must upload a document (PDF) in the supporting document upload task disclosing the use of AI and providing a description.

### **CORRESPONDENCE**

The submitting author may be contacted to clarify co-author information, role, or contributions. All correspondence regarding submitted abstracts will be directed to the submitting author, with a copy to others if requested. **Submitters may include a second person to be copied on correspondence by adding a CC email on their profile in the submission system.** Submitters may contact the abstract coordinator for questions at any time during the process.

### **REVIEW PROCESS**

#### Abstract reviews

Abstracts will be reviewed by a committee of advanced practitioners. Review of the abstract will be focused on the following questions:

- Is the content/context focused on the patient perspective?
- Is the topic relevant to and significant for the care of a patient on the cancer care continuum?

- Does the abstract describe a specific initiative, project, process, educational effort, or research that has resulted in outcomes impacting patient care and support?
- Is the initiative, project, process or educational effort described in detail within the section headings, including results, conclusions and recommendations or plans for next steps?
- Does the abstract provide necessary permissions?
- If the abstract is submitted by a patient or caregiver, is there an advocacy organization partner as co-author?

## NOTIFICATIONS

Submitting authors whose abstracts are accepted for poster presentation will be contacted by the abstract coordinator via email in August 2026.

## POSTER PRESENTATIONS

When an abstract is accepted, the poster presenter will be provided important information regarding next steps in the process, such as: poster presenter tasks, specifications for poster development, presentation dates and times, poster numbers or other identifiers, and additional requirements as needed. **The presenter must be registered for the conference to present the poster.**

### Poster presenter responsibilities

- Completing poster presenter tasks in an electronic submission system prior to the conference (see below)
- Registering for the conference
- Development and printing of the poster
- Transport or shipping of the poster to the conference venue
- Displaying the poster in the exhibit hall Thursday, October 15, between 1:00 and 4:00 PM CT
- Attending two moderated poster sessions to discuss the poster, answer questions, and interact with conference attendees, Friday, October 16 and Saturday October 17 (times to be announced)
- Bringing materials about the organization and/or available programs for a take-one table for attendees

### Poster presenter tasks

Tasks with deadlines will be completed in the electronic system, such as:

- Confirming profile information
- Uploading a presenter photo
- Uploading a presenter bio
- Uploading the final poster as a one-page image and a one-page PDF
- Recording or uploading a short, 3–5-minute audio or video statement about the poster (optional)

**Please note that the poster presenter will be the one who has access to the poster portal and must be the one to complete the tasks.**

## POSTER VISIBILITY AND BENEFITS OF PRESENTATION

Posters, abstracts, and presenting author information will be available to registered conference attendees during the live conference. Each organization may bring materials on their patient services/programs for the combined “take-one” table accessible to attendees. **One (1) all-access, Patient Advocate conference**

**registration may be provided to the presenting poster representative for access into the exhibit hall and to attend sessions** (conference activities for additional fees not included but may be available for purchase during registration).

Posters will also be available in a digital poster gallery via the conference app. In addition, posters will remain available during the JADPRO Live on-demand period October 28 through December 31, 2026. In January 2027, an email will be deployed to the JADPRO advanced practice list of 8000+ with a description of the poster tracks and a link to all posters. For questions regarding submission, please contact Kelley Moore, Event Manager, [kelley.moore@conexiant.com](mailto:kelley.moore@conexiant.com). For more information regarding patient posters and additional opportunities to interact with advanced practitioner attendees, please contact Alyssa Hulahan-Castellano via [alyssa.castellano@conexiant.com](mailto:alyssa.castellano@conexiant.com).